Hematologic response to vorinostat treatment in relapsed myeloid leukemia of Down syndrome
Children with Down syndrome are at high risk to develop myeloid leukemia (ML-DS). Despite their excellent prognosis, children with ML-DS particularly suffer from severe therapy-related toxicities and for relapsed ML-DS the cure rates are very poor. Here we report the clinical course of one child wit...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Article (Journal) |
| Lingua: | inglese |
| Pubblicazione: |
18 May 2016
|
| In: |
Pediatric blood & cancer
Year: 2016, Volume: 63, Fascicolo: 9, Pages: 1677-1679 |
| ISSN: | 1545-5017 |
| DOI: | 10.1002/pbc.26062 |
| Accesso online: | Verlag, Volltext: http://dx.doi.org/10.1002/pbc.26062 Verlag, Volltext: http://onlinelibrary.wiley.com/doi/10.1002/pbc.26062/abstract 
|
| Note sull'autore: | Carina Scheer, Christian Kratz, Olaf Witt, Ursula Creutzig, Dirk Reinhardt, and Jan-Henning Klusmann |
| Riassunto: | Children with Down syndrome are at high risk to develop myeloid leukemia (ML-DS). Despite their excellent prognosis, children with ML-DS particularly suffer from severe therapy-related toxicities and for relapsed ML-DS the cure rates are very poor. Here we report the clinical course of one child with ML-DS treated with the histone deacetylase (HDAC) inhibitor vorinostat (suberoylanilide hydroxamic acid) after second relapse. The child had previously received conventional chemotherapy and stem cell transplantation, yet showed a remarkable clinical and hematologic response. Thus, HDAC inhibitor may represent an effective class of drugs for the treatment of ML-DS. |
|---|---|
| Descrizione del documento: | Gesehen am 01.03.2018 |
| Descrizione fisica: | Online Resource |
| ISSN: | 1545-5017 |
| DOI: | 10.1002/pbc.26062 |